Tonix in-licenses Phase 2/3-ready Lyme disease antibody TNX-4800

Tonix Pharmaceuticals Holding Corp.

In-licensed worldwide rights to TNX-4800, a fully human monoclonal antibody targeting OspA of Borrelia burgdorferi.
Designed as a single subcutaneous dose each Spring to protect against Lyme disease through Fall tick season.
Positive Phase 1 study showed safety, tolerability, and linear PK/PD/efficacy relationship (1:1:1).
Planning adaptive Phase 2/3 study; ~70 million people in U.S. endemic areas eligible for treatment.
Developed by UMass Chan Medical School; no FDA-approved vaccines currently available for Lyme disease.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.